Trial Profile

Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB with OMV + MenACWY Combination Vaccination Formulations.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine groups A B C Y W-135 conjugate (Primary) ; Meningococcal vaccine group B OMV Novartis
Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
Focus Pharmacodynamics
Sponsors Novartis Vaccines

27 Oct 2011 Additional location (Poland) and actual initiaton date (Aug 2011) added as reported by ClinicalTrials.gov.
27 Oct 2011 Planned End Date changed from 1 Jul 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
27 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com